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Summary Cancer incidence among 3,727 offspring of women hospitalised for epilepsy in Denmark between
1933 and 1962 was evaluated in a record-linkage survey with the national cancer registry. The children were
identified from hospital charts, population listings, and parish registries. For all children (born before and
after their mothers' hospitalisation), no excess of cancer was found in comparison with the general population
(49 observed vs 53.8 expected). Among the 2,579 children born after their mothers' first admission for epilepsy,
and thus presumably exposed in utero to anticonvulsant drugs, 14 cancers were identified compared to 13.8
expected (relative risk 1.0; 95% confidence interval 0.6-1.7). Contrary to some previous reports, cancers of the
brain and nervous system were not significantly increased (3 observed vs 2.2 expected). These data provide no
evidence that anticonvulsant drugs are transplacental carcinogens, and indicate that overall increases in risk as
high as 80% are unlikely.
The relation of childhood neoplasms to maternal epilepsy
and use of anticonvulsants has been suggested in several
studies. In a large case-control study of childhood cancer,
prenatal exposure to anticonvulsant drugs was implicated
(Sanders & Draper, 1979), but subsequent analyses suggested
a closer relationship to maternal epilepsy rather than to its
treatment (Gilman et al., 1989). A case-control study of
childhood brain cancer revealed an association with bar-
biturate exposure in utero and in early life (Gold et al., 1978,
1979), although this finding was not confirmed in two cohort
studies (Annegers et al., 1979; Heinonen et al., 1977) or in a
recent case-control study (Goldhaber et al., 1990). Case
reports have related neuroblastoma to the fetal hydantoin
syndrome, a constellation of birth defects among offspring of
mothers receiving diphenylhydantoin (phenytoin), but it is
not clear if the association is etiologic or a chance event
(Koren et al., 1989).
Excess brain tumours have occurred in cohort studies of
epileptics treated with anticonvulsant drugs (Clemmesen et
al., 1974; White et al., 1979; Shirts et al., 1986; Olsen et al.,
1989), but the finding is complicated by the fact that seizures
may be an early manifestation of the brain tumour. Further,
some studies have suggested relationships of lung cancer
following phenobarbital use (Friedman, 1981; Olsen et al.,
1989), and lymphomas after phenytoin (Li et al., 1975). In a
large follow-up study of cancer among 8,004 epileptic
patients exposed to anticonvulsive drugs in Denmark, we
found little evidence that phenobarbitone or hydantoins are
carcinogenic to humans, although small risks of lung cancer
and non-Hodgkin's lymphoma could not be ruled out (Olsen
et al., 1989).
To clarify the potential of anticonvulsant drugs to be
transplacental carcinogens, we identified the offspring of
3,758 women hospitalised for epilepsy between 1933 and
1962.
Methods
Study population
The study population included the children of 3,758 female
patients admitted for epilepsy to the Filadelfia treatment
community in Denmark between 1933 and 1962. Details
concerning the identification and selection of the patients
have been given in earlier publications (Clemmesen &
Hjalgrim-Jensen, 1978; Olsen et al., 1989). Table I shows the
Table I Number of female patients hospitalised for epilepsy
between 1933 and 1962 at Filadelfia, Denmark by age and year of
admission
Age at Year of admission
admission 1933-42 1943-52 1953-62 Total (%)
0-19 244 560 906 1710 (45)
20-39 408 562 455 1425 (38)
40-59 122 189 257 568 (15)
>60 3 9 43 55 (2)
Total 777 1320 1661 3758 (100)
age distribution of the female patients at the time of first
admission to the epilepsy hospital over three consecutive
10-year calendar periods. Overall, 45% were below age 20
and 38% were ages 20-39 at first admittance, which is also
regarded as the time when treatment for epilepsy began.
Drug exposure
Up until the 1960s phenobarbital and hydantoins were the
principal drugs used to treat epilepsy at Filadelfia. Phenobar-
bitone was introduced in the early 1920s followed by hydan-
toins in the 1940s. In the mid-1950s, primidone, which is a
barbiturate partly converted to phenobarbitone after inges-
tion, was introduced for treatment of grand mal seizures.
Records from a sample of 130 female epileptic patients were
abstracted to obtain more detailed information on drug use.
Women hospitalised for epilepsy commonly received daily
doses of 100-300 mg of phenobarbitone, or other drugs, and
treatment often continued for life (Olsen et al., 1989).
Identifying offspring
A Central Population Register (CPR) was established in
Denmark on 1 April 1968, when all citizens were assigned a
unique 10-digit personal identification (ID) number. The
CPR includes information on vital status, addresses, and
ways to identify parents and children, if both were alive on
(or after) I April 1968 and still living in the same household
at that time.
The female epileptics were thus separated into two groups,
those with known ID numbers (n = 3,066; 82%), and those
who died before I April 1968 without an ID number
(n = 692; 18%). By means of computerised record linkage
with the CPR, a search was made for all children born
between I April 1968 and 31 December 1986.
Offspring born before the inception of the CPR were
identified through the 276 local population registers in Den-
mark. Because deceased children are not 'transferred' to a
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new population register when a family changes its place of
residence, complete residential histories were searched for all
female patients over age 17 on 1 April 1968. This tracing was
relatively complete in that residential coverage was deter-
mined for 82% of the time (on average) a woman was alive
between the ages of 18 and 50 years. Local population
registries were then contacted for information on children.
No attempt was made to trace offspring of female epileptics
deceased before 1 April 1968.
An average of 1.2 children per female epileptic was
identified, 3,727 children overall (Table II). The number of
nulliparous women was high in comparison with the general
population, 47% versus approximately 20% (Ewertz &
Jensen, 1984). Among those with children, the family size
was fairly similar to the national average (Ewertz & Duffy,
1988).
Cancer incidence andanalysis
A complete description and evaluation of the Danish Cancer
Registry have been given earlier (Jensen et al., 1985). Records
on the offspring of female epileptics were linked with the files
of the Cancer Registry following a previously established
procedure (Jensen, 1980). The period of observation for cal-
culation of the risk of developing a cancer began at date of
birth or I January 1943 (when the registry began), whichever
occurred later. The end of the period was taken as the date
of last contact, i.e. the date of death, emigration, or 31
December 1986, for those known to be alive at the study
closing date. The number of expected malignancies was cal-
culated by applying the cancer incidence rates by site, sex,
5-year age and 5-year time periods to the appropriate person-
years under observation (Monson, 1974). Statistical methods
used were based on the assumption that the observed
numbers of cancer cases in any specific category will follow a
Poisson distribution. Tests of significance and confidence
intervals (CI) for the relative risk (RR), taken as the ratio of
observed to expected individual cancers, were calculated with
the use of the exact Poisson probabilities when the observed
number of cases was small; otherwise, an accurate asymptotic
approximation was used (Rothman & Boice, 1979).
Results
The survey on drug use among a sample (n = 130) of female
epileptic patients indicated that 76% had been treated with
phenobarbitone, 59% with hydantoins, and 30% with primi-
done. Table III gives the proportion of female epileptics who
ever used one or more of the specified groups of drug during
four consecutive calendar periods, and the typical daily doses
prescribed. For 13% of the women in the sample, evidence of
anticonvulsant therapy was not apparent from their hospital
records.
Among the 3,727 offspring included in the study (1,933
boys and 1,794 girls), 3,395 (91%) were known to be alive at
the end of the study period (31 December 1986), 243 (7%)
had died, and 89 (2%) had emigrated. In the total group of
children, 1,148 were born before the initial admittance of the
mother to Filadelfia, and 2,579 after hospitalisation. A total
Table II Some characteristics of the 3,727 identified offspring of
3,066 epileptic womena
Characteristics Number Per cent
Verified children
Boys 1933 51.9
Girls 1794 48.1
Total 3727 100.0
Year of birth
1912-36 387 10.4
1937-61 1840 49.4
1962-86 1500 40.2
Vital status (31 December 1986)
Alive 3395 91.1
Deceased 243 6.5
Emigrated 89 2.4
Number of children per epileptic woman
None 1438 46.9
1 447 14.6
2 637 20.8
3 331 10.8
4 or more 213 6.9
aThe mothers of these children had to be alive on 1 April 1968 for
their offspring to be included in the study.
of 42,154 person-years of follow-up were accumulated in the
former group and 57,741 in the latter, for an average follow-
up of 37.5 years (maximum, 65) and 22.4 years (maximum,
50), respectively.
Overall, 49 cancers were identified compared to 53.8
expected (RR 0.91; 95% CI0.7-1.2). Among the group of
offspring born before the mothers' initial admission to
Filadelfia, 35 developed a cancer compared to 40.0 expected
(RR 0.88; 95% CI 0.6-1.2). No significant increase in risk
for any cancer was found, although small excesses were
noted for lung cancer (7 versus 3.2) and nonmelanoma skin
cancer (7 versus 3.8). As shown in Table IV, 14 cancers
occurred among offspring born after the mothers' initial
admission compared to 13.8 expected (RR 1.0; 95% CI
0.6-1.7). No excess risk was observed for any specific cancer.
Table V shows the tumour types, sex, age at diagnosis, and
maternal drug histories of children (born after their mothers'
initial admission) who developed cancer. Two of the three
brain cancer cases were astrocytomas; however, no anticon-
vulsants were given during pregnancy for one case, and in the
other no information on therapy was available. One of the
two children with leukaemia also had Down's syndrome.
Discussion
Since 1971 when prenatal exposure to synthetic estrogens was
linked to clear cell adenocarcinomas of the vagina and cervix
(Herbst et al., 1971), there has been great interest in whether
other drugs pose transplacental hazards. Some suspicion has
centered on phenytoin, because of clinical reports of neuro-
blastoma with the fetal hydantoin syndrome. The relation of
prenatal barbiturate exposure to childhood brain tumours
was raised by one study (Gold et al., 1978, 1979), although
not confirmed by others (Annegers et al., 1979; Heinonen et
Table III Proportion of female patients ever taking anticonvulsant drugs
during four specific time periods obtained from a sample of 130 patientsa
Time period of treatment Typical
Anticonvulsants 1933-9 1940-9 1950-9 1960-9 daily
ever taken % % % % doses (mg)
Phenobarbitone 94 80 76 59 200
Hydantoins 3 42 55 50 200
Primidone 0 0 28 27 500
Carbamazepine 0 0 0 5 800
Other drugs 3 9 9 15 -
aMay sum up to more than 100% since some patients received more than one
drug within each time period.998 J.H. OLSEN et al.
Table IV Observed (0) and expected (E) incident cancers between
1943 and 1986 among 2,579 children born after admission of their
mothers to the Filadelfia hospital
Site 0 E OIE (95% CI)
Cervix uteri 1 0.79 1.3 (0.0-7.0)
Breast 0 0.91 0.0 (0.0-4.1)
Testis 2 1.34 1.5 (0.2-5.4)
Melanoma of skin 2 0.79 2.6 (0.3-9.2)
Other skin 1 0.74 1.4 (0.1-7.0)
Brain and nervous system 3 2.17 1.4 (0.3-4.0)
Bone 1 0.38 2.7 (0.0-15)
Hodgkin's disease 1 0.77 1.3 (0.0-7.2)
Non-Hodgkin's lymphoma 0 0.64 0.0 (0.0-5.8)
Leukaemia 2 2.08 1.0 (0.1-3.5)
Other 1 3.16 0.3 (0.0-1.8)
All cancers 14 13.77 1.0 (0.6-1.7)
al., 1977; Goldhaber et al., 1990). Further interest has been
aroused by reports that after postnatal exposure hydantoins
may be related to lymphoma (Li et al., 1975), and phenobar-
bitone to lung cancer (Friedman, 1981).
In this cohort study of 3,727 children born to epileptic
mothers, we found no evidence of increased cancer risk. A
maternal history of hospitalisation for epilepsy was used as a
proxy for fetal drug exposure, and cancer was evaluated in
offspring born both before and after hospitalisation. No
forms of cancer could be linked to either a maternal history
of epilepsy or exposure in utero to anticonvulsant drugs.
However, despite the relatively large number of exposed
offspring in our study, the number of observed cancers was
relatively small, and the power to detect the relatively small
relative risks suggested in several previous studies was low.
While two-fold risks for all cancer sites combined can be
reasonably excluded in our series, lower level risks cannot.
For specific cancer sites, the upper confidence limits indicate
that three-fold and greater risks would not be incompatible
with the current observations. In addition, we could not
obtain complete drug histories on all individuals, only details
from a sample and from those mothers whose children
developed malignancy. Also, about 13% of the women who
were hospitalised for epilepsy apparently received little or no
anticonvulsant treatment, so that fetal exposures are less
certain. On the other hand, we had relatively complete
identification of children born to epileptic mothers and
relatively complete ascertainment ofcancer incidence through
linkage with available national record systems. The period of
observation was long, and cancers through early adulthood
(ages 24 through 53 years) could be identified for the
majority of offspring.
Prenatal exposures to anticonvulsants were likely to be
heaviest among the 2,579 children born after hospitalisation
of their mothers for epilepsy. This subgroup showed no
excess risk of any form of cancer. Although the developing
fetus may be especially sensitive to the effects of carcinogenic
exposures, these data suggest that if anticonvulsants are car-
cinogenic, our study size was too small to detect small inc-
reases in risk, the cumulative dose at critical periods was too
low, or the observational period was too short to accom-
modate the latency for certain forms of cancer.
Table V Cancers occurring among children born after the admission of their mothers to the Filadelfia
hospital
Anticonvulsants used
Case Age at during pregnancy
no. Site and type Sex diagnosis (daily dosage)
I Medulloblastoma of cerebellum M 9 Phenobarbitone (100 mg)
Phenytoin (300 mg)
2 Pilocystic astrocytoma of brain F 6 No indication of use
3 Astrocytoma of brain M 12 Information not available
4 Testis, seminoma M 29 Phenobarbitone (200 mg)
Phenytoin (300 mg)
5 Testis, teratocarcinoma M 26 Phenytoin (200 mg)
Primidone (250 mg)
6 Embryonal carcinoma of retroperitoneal tissue M 20 Phenytoin (300 mg)
Primidone (750 mg)
7 Acute lymphatic leukaemiaa F 7 Phenobarbitone (250 mg)
Phenytoin (50 mg)
8 Acute myeloid leukaemia F 3 Phenytoin (200 mg)
Ethosuximide (750 mg)
9 Malignant lymphogranulomatosis M 2 No indication of use
10 Skin melanoma, NOS F 25 Phenytoin (100 mg)
11 Skin melanoma, superficial spreading type F 26 No indication of use
12 Basal cell carcinoma of skin F 37 No indication of use
13 Osteogenic sarcoma of femur M 12 No indication of use
14 Cervix uteri, squamous cell carcinoma F 21 Phenobarbitone (150 mg)
aChild also had Down's syndrome.
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